NEW YORK, June 2, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities,
today announced Theralase Technologies
Inc. ("Theralase®" or the "Company") (TSX-V: TLT; OTCQX: TLTFF), a leading biotech company focused on the commercialization
of medical devices to eliminate pain and the development of Photo Dynamic Compounds ("PDCs") to destroy cancer, has qualified to
trade on the OTCQX® Best Market. Theralase upgraded to OTCQX from the Pink® market.
Theralase begins trading today on OTCQX under the symbol "TLTFF". U.S. investors can find current financial disclosure and
Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"Trading on the OTCQX will allow Theralase to build visibility and provide a more transparent market for U.S. investors," said
Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "We are
pleased to welcome Theralase to OTCQX and look forward to supporting the company and its shareholders in the public markets."
Roger Dumoulin-White, President and CEO of Theralase, stated that, "We are delighted to have
qualified for trading on OTCQX by meeting high financial standards, following best practice corporate governance guidelines,
demonstrating compliance with U.S. securities laws and having a professional third-party sponsor introduction. All of these key
characteristics of our Company will provide security and transparency for U.S. based investors that elect to trade in our
stock."
The Company was sponsored for OTCQX by Troutman Sanders LLP, a qualified 3rd party firm responsible for providing
guidance on OTCQX requirements and recommending membership.
The Company in its Therapeutic Laser Technology Division designs, manufactures, markets and distributes patented super-pulsed
laser technology indicated for the treatment of chronic knee pain and in off-label use the elimination of pain, reduction of
inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle, tendon, ligament, joint and wound
conditions. Theralase's Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic
Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink®
Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that
provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower
companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com
For More Information:
Roger Dumoulin-White, President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-theralase-technologies-inc-to-otcqx-300467647.html
SOURCE OTC Markets Group Inc.